Clinical Trial Update: Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE) [Phase 3]

View source ↗

Summary

Phase 3 trial Be-OnE evaluating switching virologically suppressed HIV-1 patients from dolutegravir-based regimens to E/C/F/TAF; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• E/C/F/TAF (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)

Snippet

Sponsor: IRCCS San Raffaele | Conditions: HIV-1-infection | Phase 3 | Status: TERMINATED